Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hodgkin Lymphoma: early-phase trial registry
28 of 72 indexed Hodgkin Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #191 of 28,707 conditions by registered trial count.
72 US clinical trials · 28 currently recruiting · #191 of 28,707 conditions by registered trial count
Hodgkin Lymphoma: 72 US clinical trials tracked, 28 recruiting.
Hodgkin Lymphoma is the subject of 72 registered US clinical trials on ClinicalTrials.gov, 28 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 58 in Phase 1-2 (earlier-stage). The most active sponsor is St. Jude Children's Research Hospital, running 7 of these trials.
Enrollment posture brief
Registry condition hodgkin-lymphoma
OPEN 28 | RECR 39% | LATE 1 | EARLY 58 | RANK #191 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Chronic Myeloid Leukemia (39% recruiting · 36 trials)
Hodgkin Lymphoma lists 28 open slots (39% of 72 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hodgkin Lymphoma recruits in line with its size-band peers.
28 of 72 indexed trials (38.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hodgkin Lymphoma trials is spread across many organizations.
St. Jude Children's Research Hospital accounts for 7 of 72 trials (9.7%). 46 distinct sponsors appear on at least one study for this condition label.
-
Most Hodgkin Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 72 trials that report a genuine target (sentinel values excluded). 52 of those (72.2%) plan for fewer than 100 participants.
-
Hodgkin Lymphoma research is mostly interventional.
67 interventional and 5 observational studies make up this index (93.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
72 total, page 1 of 2
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
ECOG-ACRIN Cancer Research Group
NCT06002828
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
University College, London
NCT04685616
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT03618550
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT06059391
Auto Stem Cell Transplant for Lymphoma Patients
Masonic Cancer Center, University of Minnesota
NCT03125642
Lifestyle Intervention of Food and Exercise for Lymphoma Survivors
University of Miami
NCT05839210
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
AstraZeneca
NCT06137144
Improving Exercise Capacity With a Tailored Physical Activity Intervention
Wake Forest University Health Sciences
NCT05595577
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Thomas Jefferson University
NCT07188090
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Baylor College of Medicine
NCT06176690
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
New York Medical College
NCT05253495
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
NCT05092451
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Marker Therapeutics
NCT05798897
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
NCT06150664
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT06377566
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
NCT05031897
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT04195633
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT05476770
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Veronika Bachanova
NCT03681561
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
VIVUS
NCT06915246
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
University of Miami
NCT07002216
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
M.D. Anderson Cancer Center
NCT05615636
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
UNC Lineberger Comprehensive Cancer Center
NCT06090864
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
NCT02508038
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Leland Metheny
NCT06680661
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Mitchell Cairo
NCT04099966
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
University of Utah
NCT05723055
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06398457
A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
St. Jude Children's Research Hospital
NCT02256137
Methionine PET/CT Studies In Patients With Cancer
St. Jude Children's Research Hospital
NCT00840047
Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
St. Jude Children's Research Hospital
NCT03361020
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study
City of Hope Medical Center
NCT04537871
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
Merck Sharp & Dohme
NCT03407144
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
NCT03755804
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT01868451
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT02506933
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
St. Jude Children's Research Hospital
NCT00846742
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
GlaxoSmithKline
NCT06521567
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Memorial Sloan Kettering Cancer Center
NCT03033914
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT03849651
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
NCT05565417
Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer
St. Jude Children's Research Hospital
NCT05550948
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Baylor College of Medicine
NCT01333046
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT03192397
Integrated Actionable Aging Assessment for Cancer Patients Pilot
University of Colorado, Denver
NCT05871008
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
City of Hope Medical Center
NCT03560752
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Bio-Path Holdings
NCT04072458
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
University of Chicago
NCT05019976
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Ohio State University Comprehensive Cancer Center
NCT05972577
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center
NCT05922904
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 32 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hodgkin Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hodgkin Lymphoma page
72 registered trials, 28 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 28 Hodgkin Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- St. Jude Children's Research Hospital sponsors the most Hodgkin Lymphoma trials on record, review their full trial history before evaluating a specific study. See St. Jude Children's Research Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hodgkin Lymphoma condition card totals 72 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.